Multisystem Processes & Disorders

Cellulitis and erysipelas: outpatient vs inpatient management

Clinical Overview and When to Suspect Cellulitis/Erysipelas

— Erysipelas is overwhelmingly streptococcal.

— Purulent cellulitis (abscess, drainage, furuncle) suggests S. aureus, with MRSA coverage required empirically in many US settings.

— Skin barrier disruption: tinea pedis, eczema, trauma, ulcers, IV drug use, surgical wounds

— Lymphedema (post-mastectomy arm cellulitis), chronic venous insufficiency

— Diabetes mellitus, obesity, peripheral arterial disease

— Immunosuppression, prior cellulitis (recurrence risk doubles with each episode)

Cellulitis is an acute bacterial infection of the deep dermis and subcutaneous tissue, while erysipelas is a more superficial infection involving the upper dermis and superficial lymphatics — both present with the classic tetrad of rubor, calor, dolor, tumor.

Predominantly caused by β-hemolytic streptococci (Group A most common, also B, C, G) and Staphylococcus aureus (including MRSA in purulent disease).

Suspect in any patient with unilateral, rapidly expanding warm erythema, especially on the lower extremity (most common site in adults) or face (erysipelas).

Common predisposing factors testable on Step 3:

Key distinction: Erysipelas has a sharply demarcated, raised, "stepped-off" border and tends to involve the face or shins with prominent lymphangitic streaking and fever at onset. Cellulitis has poorly demarcated, flat borders and more indolent systemic symptoms.

Diagnosis is clinical — no routine imaging or cultures required for uncomplicated outpatient cases.

Board pearl: Approximately 30% of suspected lower-extremity cellulitis is misdiagnosed; the most common mimic is stasis dermatitis, which is typically bilateral, chronic, and not febrile. Always ask: is this truly unilateral, acute, and tender?

On Step 3, the testable decision point is rarely "is it cellulitis?" but rather outpatient oral therapy vs admission for IV antibiotics, driven by systemic toxicity, comorbidities, and ability to tolerate PO.

Presentation Patterns and Key History

— Pain disproportionate to exam findings? → red flag for necrotizing fasciitis

— Pruritus dominant? → favors contact dermatitis or stasis dermatitis

— Bilateral involvement? → almost never cellulitis

— Portal of entry: interdigital tinea pedis, leg ulcer, insect bite, cat/dog bite, IV drug injection site, recent surgery, tattoo

— Water exposure: fresh water (Aeromonas), salt water (Vibrio vulnificus — cirrhotics!), fish handling (Erysipelothrix rhusiopathiae)

— Animal contact: cat/dog bite (Pasteurella multocida), hot tub (Pseudomonas)

— Travel/exposure: hiking with tick exposure → consider erythema migrans

— Recent surgery, IV catheter, hospitalization: raises MRSA/HA-MRSA risk

— Diabetes (esp. with foot involvement), immunosuppression, chronic lymphedema, ESRD, cirrhosis, neutropenia

— Prior cellulitis episodes (recurrence is common in lymphedema/venous insufficiency)

— Allergy history (penicillin allergy alters first-line choice)

Typical timeline: Symptoms develop over hours to a few days, with progressive erythema, warmth, swelling, and pain at the affected site. Erysipelas onset is more abrupt with high fever and chills preceding the rash.

Localized symptoms to elicit:

Systemic symptoms: fever, chills, malaise, anorexia. Absence of fever does not rule out cellulitis — many outpatient cases are afebrile.

Critical historical elements (Step 3 stem clues):

Comorbidity history determines disposition:

Medication review: anticoagulants (alters drainage decisions), recent antibiotics (resistance risk), immunosuppressants.

Step 3 management: A stem describing a cirrhotic patient who ate raw oysters developing rapidly progressive lower-extremity cellulitis with hemorrhagic bullae = Vibrio vulnificus — admit, IV doxycycline + ceftriaxone, surgical consult.

Board pearl: Recurrent cellulitis in the same leg should prompt evaluation and treatment of interdigital tinea pedis — the most modifiable risk factor — plus compression for underlying lymphedema or venous insufficiency.

Physical Exam Findings and Hemodynamic Assessment

— Cellulitis: flat, ill-defined erythema; warmth; tenderness; pitting edema; may have lymphangitic streaking proximally; regional lymphadenopathy

— Erysipelas: raised, sharply demarcated peau d'orange plaque, often on face (butterfly distribution) or shin; may have bullae or vesicles

— Class I: no systemic signs, no uncontrolled comorbidities → outpatient PO

— Class II: systemically unwell OR significant comorbidity → short admission or observation

— Class III: significant systemic toxicity (tachycardia, hypotension, confusion, acidosis) → admit for IV therapy

— Class IV: sepsis or life-threatening infection (e.g., necrotizing fasciitis) → ICU + surgery

— Pain out of proportion to skin findings

— Crepitus (gas-forming organisms — clostridia, mixed anaerobes)

— Bullae, especially hemorrhagic

— Skin anesthesia over the affected area, dusky/violaceous skin, rapid progression over hours

— Systemic toxicity disproportionate to skin appearance

Inspect the affected area with the borders marked (use a skin marker) at initial visit — allows objective assessment of progression or improvement at follow-up within 24–48 hours.

Classic findings:

Always examine for the portal of entry: check interdigital spaces for tinea/maceration, scan for ulcers, abrasions, insect bites, IV track marks.

Assess severity using the Eron classification (drives disposition):

Vital signs are decision-critical: temperature, heart rate, blood pressure, respiratory rate, mental status → screen for SIRS/sepsis (qSOFA, NEWS2).

Red flags mandating immediate surgical evaluation:

Key distinction: Necrotizing fasciitis can mimic early cellulitis but progresses over hours, with disproportionate pain, systemic toxicity, and skin anesthesia — the only definitive intervention is emergent surgical debridement, not antibiotics alone.

Document neurovascular status distal to the lesion, particularly in extremity cellulitis with significant swelling — rule out compartment syndrome.

CCS pearl: When the simulated patient has cellulitis with hypotension, order fluids, blood cultures, broad IV antibiotics, lactate, and surgical consult in the first clock interval — don't delay imaging that can wait.

Diagnostic Workup — Initial Labs and Imaging

— CBC (leukocytosis, left shift)

— BMP (renal function for dosing, electrolytes)

— CRP (elevated; useful for monitoring response, though nonspecific)

— Lactate if SIRS/sepsis criteria met

— Blood cultures if febrile, immunocompromised, animal/water exposure, or suspected bacteremia (yield only ~5% overall but higher in toxic patients)

— Glucose/HbA1c in diabetics — uncontrolled hyperglycemia worsens outcomes

— HIV testing if recurrent or atypical

— Ultrasound: differentiates abscess vs phlegmon ("cobblestoning") — helps decide whether incision and drainage is needed; also evaluates for DVT

— Plain radiographs: look for soft-tissue gas or osteomyelitis if foot ulcer/diabetic

— CT or MRI: when necrotizing fasciitis, deep abscess, or osteomyelitis is suspected — MRI is most sensitive for osteomyelitis and deep infection

— MRI is gold standard for soft-tissue infection extent but should not delay surgical consult if necrotizing infection suspected

Uncomplicated outpatient cellulitis requires no labs or imaging — diagnosis is clinical. Treating empirically is appropriate and cost-effective.

Order labs when admission is being considered or systemic illness is present:

Wound/abscess cultures: Indicated when purulent material is present — culture and Gram stain guide MRSA-directed therapy. Do not culture intact skin or aspirate erythematous areas (low yield, false positives).

Imaging is not routine. Use selectively:

The LRINEC score (Lab Risk Indicator for Necrotizing Fasciitis): uses CRP, WBC, hemoglobin, sodium, creatinine, glucose. Score ≥6 raises suspicion; ≥8 is high risk — but clinical judgment trumps the score; do not exclude necrotizing fasciitis based on LRINEC alone.

Board pearl: In a diabetic with a foot ulcer and overlying cellulitis, probe-to-bone test positivity has high specificity for osteomyelitis — combine with plain films and consider MRI; treatment duration changes dramatically (4–6 weeks IV vs 5–14 days PO).

Step 3 management: Don't order imaging for every cellulitis — order ultrasound when fluctuance or abscess is unclear; order MRI/CT only with clinical concern for deep or necrotizing process.

Diagnostic Workup — Advanced or Confirmatory Studies

— Wrong diagnosis (stasis dermatitis, DVT, gout, contact dermatitis)?

— Wrong organism (MRSA, Pseudomonas, atypical mycobacteria, fungal)?

— Undrained abscess or foreign body?

— Inadequate dosing or absorption?

— Deeper infection — osteomyelitis, septic arthritis, pyomyositis, necrotizing fasciitis?

— Repeat ultrasound or obtain MRI to evaluate deeper structures

— Skin biopsy with tissue culture (bacterial, fungal, AFB) — especially in immunocompromised

— Blood cultures if not previously obtained

— Anti-streptolysin O (ASO) and anti-DNase B titers — confirm recent strep infection in recurrent erysipelas (rarely needed acutely)

— Tinea pedis — topical or oral antifungals

— Lymphedema — compression, manual lymph drainage

— Chronic venous insufficiency — compression stockings

— Obesity, diabetes — optimize control

— Consider prophylactic penicillin V 250–500 mg BID or benzathine penicillin G IM monthly

Most cellulitis cases never need advanced studies; reserve for non-responders, atypical presentations, or recurrent disease.

If patient fails to improve after 48–72 hours of appropriate antibiotics, reassess:

Studies in non-responders:

Venous duplex ultrasound: order when DVT mimics cellulitis — unilateral leg swelling/erythema in a postoperative or immobile patient. Cellulitis and DVT can coexist.

Echocardiogram: consider in cellulitis with bacteremia (especially S. aureus) to rule out endocarditis — staphylococcal bacteremia in particular mandates evaluation for endocarditis and metastatic infection.

In recurrent cellulitis (≥3 episodes/year): evaluate for and treat predisposing conditions:

Key distinction: A "cellulitis" that doesn't respond to antibiotics and lacks fever may actually be eosinophilic cellulitis (Wells syndrome), carcinoma erysipeloides (cutaneous metastasis), or lipodermatosclerosis — biopsy is diagnostic.

Board pearl: S. aureus bacteremia requires (1) repeat blood cultures to document clearance, (2) TEE to assess for endocarditis, (3) ID consult, and (4) minimum 14 days IV therapy even if uncomplicated.

Risk Stratification and Disposition Logic

— No systemic toxicity (afebrile or low-grade, normal mental status, hemodynamically stable)

— Able to tolerate PO and adhere to therapy

— No rapidly progressing infection

— Reliable follow-up within 24–48 hours

— No significant immunocompromise

— No concern for necrotizing infection or deep abscess

— Systemic signs of infection (fever >38°C, tachycardia, hypotension)

— Failure of outpatient therapy after 48–72 hours

— Inability to tolerate PO (vomiting, NPO)

— Significant comorbidity: diabetes with foot involvement, immunosuppression, cirrhosis, neutropenia, ESRD

— Rapidly progressing infection despite outpatient therapy

— Concern for necrotizing infection, deep abscess, osteomyelitis

— Extremes of age, frailty, unable to self-care

— Facial cellulitis with orbital involvement, hand cellulitis with tendon sheath concern

— Sepsis or septic shock

— Necrotizing fasciitis (also urgent OR)

— Need for aggressive resuscitation, vasopressors, or close monitoring

Disposition is the highest-yield Step 3 decision: outpatient PO antibiotics vs admission for IV therapy.

Outpatient (Eron Class I) criteria — all must be met:

Admit for IV antibiotics (Eron Class II–III) if any of:

ICU admission (Eron Class IV):

Consider observation unit / hospital-at-home / OPAT (outpatient parenteral antibiotic therapy) for borderline cases — increasingly used in value-based systems.

Step 3 management: A 65-year-old with lower-extremity cellulitis, HR 105, T 38.5, glucose 320, mild AKI — admit for IV antibiotics, glycemic control, and IV fluids; this is Eron Class II–III.

Board pearl: Facial cellulitis in adults, periorbital/orbital cellulitis, hand cellulitis with deep space involvement, and perineal cellulitis (Fournier's) generally warrant admission regardless of other parameters due to risk of severe complications.

Document the rationale for outpatient vs inpatient — Step 3 stems test recognition of who cannot safely go home.

Pharmacotherapy — First-Line Drug Regimens

— Outpatient: cephalexin 500 mg PO QID × 5–7 days (preferred); alternatives dicloxacillin 500 mg QID, amoxicillin-clavulanate if bite-related, clindamycin 300–450 mg QID if penicillin allergy

— Inpatient: cefazolin 1–2 g IV q8h; or ceftriaxone 1–2 g IV daily for convenience

— Add MRSA coverage only if systemic toxicity, prior MRSA, or failure of initial therapy

— Outpatient: TMP-SMX DS 1–2 tabs BID, doxycycline 100 mg BID, or clindamycin 300–450 mg QID × 5–7 days

— Inpatient/severe: vancomycin (15–20 mg/kg q8–12h, trough 15–20) or linezolid 600 mg q12h; daptomycin 6 mg/kg/day if persistent bacteremia (but not for pneumonia)

— Always incise and drain abscesses ≥2 cm or with surrounding cellulitis — drainage is the primary therapy

— Cat/dog bite: amoxicillin-clavulanate (covers Pasteurella, oral anaerobes); alternative doxycycline + metronidazole

— Water exposure (fresh): ciprofloxacin + doxycycline (Aeromonas)

— Water exposure (salt) or oyster ingestion in cirrhotic: ceftriaxone + doxycycline (Vibrio)

— Diabetic foot infection (moderate-severe): piperacillin-tazobactam or ceftriaxone + metronidazole, add MRSA coverage

Choice depends on purulent vs non-purulent and MRSA risk.

Non-purulent cellulitis (no abscess/drainage) — covers β-hemolytic strep ± MSSA:

Purulent cellulitis/abscess — covers MRSA:

Erysipelas: penicillin V 500 mg PO QID or amoxicillin 500 mg TID × 5 days; IV penicillin G for severe disease

Special exposures:

Duration: typically 5–7 days for uncomplicated cellulitis; extend to 10–14 days for slow responders or comorbidities. IDSA supports 5 days when improving — avoid unnecessary courses.

Board pearl: Elevation of the affected limb improves drainage of edema and accelerates resolution — a frequently missed but evidence-based adjunct. Combine with treatment of tinea pedis.

Step 3 management: Don't add empiric MRSA coverage to every non-purulent cellulitis — RCT data show no benefit of adding TMP-SMX to cephalexin in typical outpatients.

Adjunctive Procedures and Expanded Pharmacology

— Indicated for fluctuant abscesses ≥2 cm, perirectal, pilonidal, or deep abscesses

— Antibiotics added when: surrounding cellulitis, systemic signs, multiple lesions, immunocompromise, very young/old, abscess in difficult-to-drain area (face, hand, genitalia), failed prior drainage

— Small abscesses without cellulitis: I&D alone may suffice, but adding TMP-SMX or clindamycin improves cure rates per RCT data

— Empiric regimen: vancomycin + piperacillin-tazobactam + clindamycin (clindamycin suppresses toxin production in strep/staph)

— Consider IVIG in streptococcal toxic shock syndrome

— NSAIDs controversial — may mask progression of necrotizing infection; avoid in suspicious cases

— Tetanus prophylaxis if wound-associated

— Update vaccines (pneumococcal, influenza) per routine

— Penicillin V 250 mg BID or erythromycin 250 mg BID for ≥3 episodes/year (PATCH trial supports prophylaxis; benefit wanes after discontinuation)

— Concurrently address lymphedema, tinea pedis, venous insufficiency

Incision and drainage (I&D) is the cornerstone of abscess management:

Surgical debridement is the definitive treatment for necrotizing fasciitis — antibiotics alone are inadequate; delay >24 hours dramatically increases mortality.

Hyperbaric oxygen: adjunctive in clostridial myonecrosis or refractory necrotizing infections at specialized centers — does not delay surgery.

Adjunctive considerations:

Outpatient parenteral antibiotic therapy (OPAT): patients clinically stable but needing IV therapy can be discharged with home infusion of ceftriaxone, ertapenem, or daptomycin — reduces costs and nosocomial risk.

Recurrent cellulitis prophylaxis:

CCS pearl: For a patient with cellulitis and an abscess, your CCS order set should include: (1) I&D with culture, (2) appropriate antibiotic (MRSA-active if purulent), (3) tetanus prophylaxis, (4) pain control, (5) limb elevation, (6) follow-up in 48 hours, (7) return precautions for worsening pain, fever, spreading erythema.

Board pearl: Adding TMP-SMX to I&D for skin abscesses (DMID trial) modestly improves cure — guidelines now recommend antibiotic adjunct in most clinically significant abscesses.

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher baseline rates of lymphedema, venous insufficiency, diabetes, immune senescence

— May present atypically — minimal fever, confusion, functional decline rather than classic systemic signs

— Lower threshold for admission; consider functional status, ability to take PO, social support

— Polypharmacy increases drug interaction risk — review for warfarin (TMP-SMX interaction), statins (clarithromycin), QT-prolonging meds

— Cephalexin: reduce in CrCl <50 (e.g., 500 mg q12h)

— TMP-SMX: reduce in CrCl <30, avoid in CrCl <15; monitor potassium (hyperkalemia risk) and creatinine

— Vancomycin: dose by weight, target AUC 400–600 mg·h/L (modern guideline) or trough 15–20 for severe infection; nephrotoxic — monitor levels and renal function

— Piperacillin-tazobactam: renal dose adjustment; combination with vancomycin increases AKI risk — consider cefepime alternative

— Daptomycin: dose q48h if CrCl <30; monitor CK weekly (myopathy)

— Clindamycin, doxycycline, linezolid: no renal adjustment needed

— Clindamycin, erythromycin, doxycycline — use with caution in severe hepatic disease

— Linezolid: monitor for hepatotoxicity, lactic acidosis with prolonged use (>14 days)

— TMP-SMX: hepatotoxic; caution in cirrhosis

— Cirrhotic patients with salt-water exposure → consider Vibrio vulnificus empirically (ceftriaxone + doxycycline); mortality exceeds 50%

Elderly patients carry higher risk of complicated cellulitis and adverse outcomes:

Renal impairment — dose adjustments are commonly tested:

Hepatic impairment:

Avoid fluoroquinolones in elderly when possible — tendinopathy, QT prolongation, aortic aneurysm/dissection, dysglycemia, delirium, and C. difficile risks.

Step 3 management: In an 80-year-old with CKD stage 4 and cellulitis, choose cephalexin (renal-dose adjusted) over TMP-SMX (hyperkalemia + Cr bump) for non-purulent disease; if MRSA needed, use linezolid (no renal adjustment).

Board pearl: Elderly cellulitis patients with delirium and minimal fever may have occult sepsis — check lactate and admit.

Special Populations — Pregnancy, Pediatrics, and Immunocompromised

— Cellulitis is treated with β-lactams — cephalexin, dicloxacillin, amoxicillin-clavulanate are category B, safe across trimesters

— Clindamycin safe; use if penicillin-allergic

— Avoid: tetracyclines (teeth/bone), fluoroquinolones (cartilage data), TMP-SMX (1st trimester — neural tube defects; near term — kernicterus). TMP-SMX may be used cautiously in 2nd trimester with folate supplementation if necessary

— Vancomycin is acceptable for severe MRSA infection in pregnancy

— Mastitis in lactating women: dicloxacillin or cephalexin; continue breastfeeding to maintain drainage

— S. aureus (including community MRSA) and GAS dominate

— Periorbital (preseptal) cellulitis in children: usually H. influenzae, S. pneumoniae, S. aureus → outpatient amoxicillin-clavulanate if mild; admit if orbital signs (proptosis, ophthalmoplegia, vision change, pain with eye movement) → CT orbits, IV antibiotics, ENT/ophthalmology consult

— Buccal cellulitis with bluish hue in unvaccinated child → consider H. influenzae type b

— Dosing: cephalexin 25–50 mg/kg/day divided QID; clindamycin 30–40 mg/kg/day TID; TMP-SMX 8–12 mg/kg/day of TMP component divided BID

— Broader empiric coverage — include Pseudomonas (cefepime, piperacillin-tazobactam)

— Atypical organisms: fungal, mycobacterial, Cryptococcus, Nocardia, Bartonella

— Lower threshold for biopsy and tissue culture

— Admit and consult ID

Pregnancy:

Pediatrics:

Immunocompromised hosts (neutropenia, transplant, HIV, biologic therapy):

Diabetic foot infections: stratified by severity (mild/moderate/severe per IDSA). Mild: oral cephalexin or amoxicillin-clavulanate. Moderate-severe: IV broad-spectrum (pip-tazo or carbapenem) + MRSA coverage; assess for osteomyelitis.

Key distinction: Orbital cellulitis (postseptal — proptosis, painful eye movement, vision changes) vs preseptal cellulitis (eyelid swelling/erythema, normal eye movement, no proptosis) — orbital requires emergent admission, CT, and IV antibiotics.

Board pearl: Recurrent staphylococcal skin abscesses in children → consider hyper-IgE (Job) syndrome or chronic granulomatous disease; nasal MRSA decolonization with mupirocin + chlorhexidine baths helps recurrent household disease.

Complications and Adverse Outcomes

— Abscess formation — fluctuance, requires I&D

— Lymphangitis — proximal red streaking

— Lymphadenitis — tender regional nodes

— Bullae and skin necrosis — particularly in erysipelas or severe disease

— Chronic lymphedema post-infection — predisposes to recurrence (vicious cycle)

— Necrotizing fasciitis — surgical emergency; mortality 20–40%

— Myositis/pyomyositis — deep muscle infection (S. aureus); MRI diagnostic

— Septic arthritis — joint involvement requires arthrocentesis and surgical washout

— Osteomyelitis — especially in diabetic foot, requires prolonged antibiotics

— Tenosynovitis (hand) — Kanavel's signs; hand surgery emergency

— Bacteremia — 2–5% of admitted cellulitis cases; S. aureus bacteremia mandates TEE and ID consult

— Sepsis/septic shock — fluid resuscitation, broad antibiotics, vasopressors

— Streptococcal toxic shock syndrome (STSS) — hypotension, multi-organ failure with GAS; add clindamycin for toxin suppression; consider IVIG

— Endocarditis — particularly in IVDU or prosthetic valve patients

— Post-streptococcal glomerulonephritis — 1–3 weeks after skin infection; cola-colored urine, hypertension, edema, low C3. Importantly, antibiotic treatment does not prevent PSGN (unlike acute rheumatic fever, which is prevented by treating strep pharyngitis)

— Antibiotic-associated C. difficile — clindamycin highest risk

— Rash, hypersensitivity — TMP-SMX (SJS/TEN), β-lactams

— AKI — vancomycin, pip-tazo combination

— Hyperkalemia — TMP-SMX, especially with ACE-I, ARB, K-sparing diuretics

Local complications:

Deep extension:

Systemic complications:

Treatment complications:

Recurrence affects 8–20% of patients within 2 years — drives need for prophylaxis and risk factor modification.

Key distinction: PSGN can follow skin or pharyngeal strep infection; acute rheumatic fever only follows pharyngeal. Antibiotics prevent ARF but not PSGN.

Board pearl: Persistent fever and pain despite 48–72 hours of appropriate antibiotics → image for abscess, osteomyelitis, or necrotizing infection; don't simply broaden antibiotics.

When to Escalate Care — ICU, Consult, Inpatient Triage

— Septic shock (hypotension despite fluids, lactate >4, need for vasopressors)

— Necrotizing soft tissue infection with hemodynamic instability

— Respiratory failure or altered mental status

— DIC, multi-organ dysfunction

— Suspected necrotizing fasciitis — do not wait for imaging

— Compartment syndrome signs

— Deep abscess requiring drainage in OR

— Fournier's gangrene (perineal/scrotal necrotizing infection) — urology + general surgery

— Hand tenosynovitis (Kanavel's signs: flexed posture, tenderness along sheath, pain with passive extension, fusiform swelling) — hand surgery

— Diabetic foot with deep infection, osteomyelitis, or gangrene — podiatry/vascular

— S. aureus bacteremia

— Failed empiric therapy

— Atypical exposures (water, animal, travel)

— Recurrent infection

— Immunocompromised host

— Hemodynamically unstable → ICU

— Stable but needs IV, monitoring, or comorbidity management → floor admission

— Stable, mild illness, comorbidities controlled → observation or discharge with 24–48h follow-up

Immediate ICU admission for:

Surgical consult (emergent):

Ophthalmology + ENT consult: orbital cellulitis with vision change, proptosis, or restricted EOM

ID consult:

Vascular surgery / IR: when arterial insufficiency contributes to non-healing ulcer with cellulitis

Triage decision-making in CCS-style cases:

Step 3 management: A 60-year-old with diabetes presents with foot cellulitis, foul drainage, HR 115, BP 90/55, lactate 3.5. Orders: IV crystalloid bolus, blood cultures, broad-spectrum IV antibiotics (vancomycin + pip-tazo), lactate trend, surgical consult for debridement, ICU admission. Initiate early goal-directed sepsis bundle within 1 hour.

CCS pearl: Don't forget the "soft" orders — limb elevation, marking erythema borders, glycemic control, DVT prophylaxis, pressure ulcer prevention, smoking cessation counseling. These show up as scored items.

Board pearl: Time-to-debridement is the strongest modifiable predictor of survival in necrotizing fasciitis — <24 hours dramatically reduces mortality.

Key Differentials — Same-Category (Skin/Soft Tissue) Causes

— Bilateral, chronic, usually afebrile

— Hyperpigmentation, scaling, pruritus, varicosities

— Treatment: compression, leg elevation, topical steroids — not antibiotics

— Periorbital vs orbital — distinguished by ophthalmoplegia, proptosis, visual changes

— Perianal/Fournier's — perineal necrotizing infection

Stasis dermatitis — the #1 mimic of lower-extremity cellulitis:

Contact dermatitis — pruritus dominant, well-demarcated borders following exposure pattern (e.g., poison ivy line); vesicles common

Lipodermatosclerosis — chronic woody induration of medial calf in venous insufficiency; "inverted champagne bottle" leg; not infectious

Erysipeloid — caused by Erysipelothrix rhusiopathiae in fish handlers/butchers; violaceous, well-demarcated hand lesion; treat with penicillin or amoxicillin

Necrotizing fasciitis — pain out of proportion, rapid progression, systemic toxicity, bullae, crepitus — surgical emergency

Cellulitis variants:

Abscess/furuncle/carbuncle — purulent, fluctuant, requires drainage

Erythema migrans (Lyme) — expanding annular targetoid lesion after tick exposure, often painless and afebrile; treat doxycycline 100 mg BID × 10 days

Herpes zoster — dermatomal, vesicular, painful — antibiotics won't help; treat valacyclovir 1 g TID × 7 days

Erysipelas vs cellulitis: sharply demarcated, raised (erysipelas) vs ill-defined, flat (cellulitis)

Eosinophilic cellulitis (Wells syndrome) — recurrent "cellulitis" not responding to antibiotics; eosinophilia; biopsy shows flame figures; treat with steroids

Sweet syndrome (acute febrile neutrophilic dermatosis) — tender erythematous plaques, fever, leukocytosis, but biopsy shows neutrophilic infiltrate; associated with malignancy/IBD; treat steroids

Cutaneous T-cell lymphoma / carcinoma erysipeloides — biopsy when chronic, non-responsive

Key distinction: Antibiotic non-response over 48–72 hours despite appropriate dosing should prompt re-examination of the diagnosis as much as a search for resistant organisms.

Board pearl: Bilateral lower-extremity "cellulitis" is almost never cellulitis — it's stasis dermatitis. Don't admit for IV antibiotics; prescribe compression and leg elevation.

Key Differentials — Other-Category Causes

— Unilateral calf swelling, warmth, possible erythema

— Wells score guides workup; D-dimer + duplex ultrasound to confirm/exclude

— Cellulitis and DVT can coexist — high index of suspicion in postoperative or immobile patients

— Acute monoarticular pain with overlying erythema (1st MTP for gout; knee/wrist for pseudogout)

— Hyperuricemia/diuretic use; arthrocentesis with negatively birefringent needle-shaped crystals (gout) or positively birefringent rhomboid crystals (CPPD)

— Treat with NSAIDs, colchicine, or steroids — not antibiotics

— Inflammatory breast cancer — peau d'orange breast erythema not responding to antibiotics → urgent skin punch biopsy

— Cutaneous metastasis (carcinoma erysipeloides)

Deep vein thrombosis (DVT):

Gout/pseudogout:

Septic arthritis — monoarticular, fever, decreased ROM; arthrocentesis with WBC >50,000 → orthopedic emergency

Acute compartment syndrome — disproportionate pain, paresthesias, pallor, paralysis, pulselessness (late) — surgical emergency (fasciotomy)

Ruptured Baker's cyst — sudden calf pain mimicking DVT/cellulitis; ultrasound diagnostic

Hematoma — recent trauma or anticoagulant use; ecchymosis evolves through color changes

Drug reactions — DRESS, SJS/TEN: systemic illness, mucosal involvement, drug exposure history

Erythema nodosum — bilateral tender pretibial nodules; associated with sarcoidosis, IBD, infections, drugs

Panniculitis — subcutaneous fat inflammation from various causes

Calciphylaxis — ESRD patient with painful violaceous plaques progressing to necrotic ulcers; biopsy diagnostic; high mortality

Cellulitis-like presentations of malignancy:

Vasculitis — palpable purpura, livedo, systemic features; biopsy and serology

Key distinction: Inflammatory breast cancer mimics mastitis/cellulitis but doesn't respond to antibiotics in 1–2 weeks — biopsy is mandatory; do not repeatedly treat with antibiotics.

Step 3 management: A postoperative patient with unilateral leg swelling, warmth, and mild erythema → obtain venous duplex before assuming cellulitis; cellulitis without portal of entry in this setting is uncommon.

Board pearl: When in doubt, mark the borders and reassess in 24–48 hours — true cellulitis improves on antibiotics; mimics don't.

Secondary Prevention, Discharge Plan, and Long-Term Management

— Complete prescribed antibiotic course (5–7 days typical; longer if comorbidities or complicated)

— Topical antifungal if tinea pedis identified (clotrimazole, terbinafine) — addresses portal of entry

— Analgesics (acetaminophen, limited NSAIDs)

— Update tetanus prophylaxis if wound-associated

— Treat tinea pedis aggressively — single most modifiable risk factor for recurrent cellulitis

— Compression stockings (20–30 or 30–40 mmHg) for venous insufficiency and lymphedema — apply after edema resolves

— Skin care: daily inspection, moisturization, prompt treatment of cuts and abrasions

— Weight management for obesity-associated lymphedema

— Glycemic control — A1c <7% reduces recurrence in diabetics

— Foot care education for diabetics — daily inspection, well-fitting shoes, podiatry referral

— Treat venous reflux — endovenous ablation in select patients

— Penicillin V 250 mg BID or erythromycin 250 mg BID — PATCH trial showed 45% reduction in recurrence while on therapy

— Benefit wanes after discontinuation; consider indefinite use in persistently high-risk patients

— Alternative: benzathine penicillin G 1.2 million units IM monthly

Discharge medications:

Risk factor modification — the highest-yield long-term step:

Antibiotic prophylaxis for recurrent cellulitis (≥3 episodes/year despite risk-factor optimization):

Vaccinations: ensure pneumococcal, influenza, COVID up to date; tetanus booster every 10 years

Lymphedema therapy — manual lymph drainage, multilayer bandaging, pneumatic compression — refer to lymphedema specialist

Smoking cessation — improves vascular health and wound healing

Health system considerations: wound care nursing follow-up; OPAT clinics; chronic disease management referral

Step 3 management: Discharge orders for cellulitis should include: PO antibiotic with duration, topical antifungal if tinea pedis, compression after acute swelling resolves, primary care follow-up in 1 week, return precautions (worsening pain, fever, spreading erythema, streaking), and diabetes/wound clinic referral if applicable.

Board pearl: Treating tinea pedis prevents more recurrences than any antibiotic regimen — examine the toe webs at every visit.

Follow-Up, Monitoring, and Counseling

— Compare erythema to marked border at original visit

— Reassess pain, fever, ability to tolerate PO, adherence

— If progression or no improvement → escalate (admit, expand coverage, image, drain)

— Improvement in 48–72 hours with appropriate antibiotic and supportive care

— Erythema may actually expand slightly in first 24 hours as inflammation peaks — distinguish from true progression by systemic signs and rate

— Complete resolution: 7–14 days; residual hyperpigmentation may persist weeks

— Primary care visit within 1–2 weeks

— Wound care clinic if ulcer, drainage site, or diabetic foot

— ID follow-up if S. aureus bacteremia, OPAT, or recurrent infection

— Repeat blood cultures 48–72 hours after starting therapy for documented bacteremia (especially S. aureus) to ensure clearance

— Vital signs trend, CBC normalization, CRP/WBC trend

— For OPAT: weekly CBC, BMP, LFTs, and drug-specific monitoring (vancomycin troughs/AUC, daptomycin CK, linezolid CBC for myelosuppression with use >2 weeks)

— Glucose control in diabetics

— Renal function on nephrotoxic agents

— Adherence to full antibiotic course

— Limb elevation, hydration, rest

— Return precautions — fever, expanding erythema beyond marked border, streaking, severe pain, new bullae, dyspnea, confusion

— Recognition of recurrence — early presentation prevents complications

— Skin care and tinea pedis treatment

— Compression stocking use after acute phase

— Lymphedema therapy if persistent swelling

— Physical therapy for deconditioning after prolonged admission

— Smoking cessation counseling

Initial follow-up: 24–48 hours after starting outpatient therapy — telehealth or in-person assessment of response.

Expected response timeline:

Post-discharge follow-up after admission:

Monitoring parameters:

Patient counseling:

Rehabilitation considerations:

CCS pearl: Always schedule a 48-hour follow-up for any outpatient cellulitis — failure to do so is a scored safety issue. Document return precautions explicitly.

Board pearl: Failure to improve in 48–72 hours is the most testable trigger to reassess diagnosis, drain occult abscess, or expand to MRSA coverage.

Ethical, Legal, and Patient Safety Considerations

— At discharge, ensure clear written instructions on antibiotic dose/duration, return precautions, follow-up appointment, and contact info

— Reconcile medications — many cellulitis patients are elderly with polypharmacy; check warfarin (interactions with TMP-SMX, fluoroquinolones, macrolides), statins, oral hypoglycemics

— Verify patient understands with teach-back

— Use after-visit summary and patient portal

— Avoid unnecessarily broad coverage (MRSA add-ons when not indicated)

— Use shortest effective duration (5–7 days for uncomplicated)

— Document indication and stop date in the chart

— Stewardship reduces C. difficile, resistance, and adverse drug events

— I&D requires consent including risks (bleeding, scarring, recurrence, anesthesia reaction)

— Surgical debridement for necrotizing fasciitis is emergent; if patient lacks capacity, proceed under emergency exception with documentation; involve surrogate decision-maker ASAP

— Pediatric I&D requires parental consent except in emergency

— Suspected child abuse or elder abuse when injury pattern doesn't match story (e.g., cigarette burns presenting as cellulitis) — mandatory reporting

— IV drug use as portal of entry — offer harm reduction, addiction treatment referral; not reportable but ethically engage

— Reportable diseases: most cellulitis is not reportable, but necrotizing GAS infection is reportable in many jurisdictions

— Cellulitis disproportionately affects patients with limited access to wound care, diabetic foot services, and primary care

— Consider social determinants — housing, food security, transportation to follow-up

— Connect patients with community resources and case management

— DVT prophylaxis during hospitalization

— Falls prevention in elderly

— Pressure ulcer prevention with immobility

— Hand hygiene and contact precautions for MRSA

Transition-of-care safety is a major Step 3 testable domain:

Antibiotic stewardship:

Informed consent for procedures:

Mandatory reporting and adjacent issues:

Health equity:

Patient safety in inpatient management:

CCS pearl: Capacity assessment is required before allowing a patient with cellulitis and possible sepsis to refuse admission — document capacity, risks discussed, and offer to return.

Board pearl: Failure to arrange 48-hour outpatient follow-up after starting therapy is a recurring "safety" wrong answer; it's the safety net that catches treatment failures before they become admissions.

High-Yield Associations and Rapid-Fire Facts

Cat bite → Pasteurella multocida → amoxicillin-clavulanate

Dog bite → Pasteurella, Capnocytophaga (esp. in asplenics — fulminant sepsis) → amox-clav

Human bite → Eikenella corrodens → amox-clav; clenched-fist injury → hand surgery consult

Fresh water exposure with wound → Aeromonas hydrophila → ciprofloxacin + doxycycline

Salt water exposure or raw oysters + cirrhosis → Vibrio vulnificus → ceftriaxone + doxycycline

Fish handler / butcher → Erysipelothrix rhusiopathiae → penicillin

Hot tub folliculitis → Pseudomonas aeruginosa → self-limited; treat if severe with ciprofloxacin

Puncture wound through sneaker → Pseudomonas osteomyelitis → ciprofloxacin

Sickle cell disease osteomyelitis → Salmonella > S. aureus

IV drug use → S. aureus (including MRSA), tricuspid endocarditis — TEE

Periorbital cellulitis in unvaccinated child → H. influenzae type b

Recurrent skin abscesses → MRSA decolonization (mupirocin, chlorhexidine baths); consider Job's syndrome if eczema + cold abscesses + high IgE

Diabetic foot polymicrobial → MRSA + GNR + anaerobes

Toxic shock with cellulitis → clindamycin for toxin suppression + IVIG

PSGN after skin strep — antibiotics don't prevent it (unlike ARF after pharyngitis)

PATCH trial — penicillin prophylaxis reduces recurrence by ~45%

DMID trial — TMP-SMX after I&D improves cure for small abscesses

LRINEC ≥6 — concern for necrotizing fasciitis (but clinical judgment overrides)

Eron classification drives admission decisions (I outpatient → IV ICU)

Inflammatory breast cancer mimics mastitis — biopsy if no response

Tinea pedis = #1 modifiable risk factor for recurrent leg cellulitis

Most common organism overall in cellulitis = β-hemolytic strep (esp. GAS)

Most common in purulent cellulitis = S. aureus (consider MRSA)

Erysipelas = strep, sharp borders, face/shin

NSAIDs may mask necrotizing infection — avoid if suspicious

Board pearl: Memorize the exposure-to-organism table — these are pattern-recognition questions on Step 3.

Board Question Stem Patterns

Stem 1 — outpatient vs inpatient triage: "A 55-year-old with diabetes presents with leg cellulitis. T 38.0, HR 90, BP 130/80, glucose 180, no vomiting. Best next step?" → Outpatient cephalexin with 48-hour follow-up; Eron Class I.

Stem 2 — purulent vs non-purulent: "A patient has a 3-cm fluctuant abscess with surrounding erythema." → I&D + TMP-SMX or clindamycin (MRSA coverage).

Stem 3 — necrotizing fasciitis trigger: "Pain out of proportion, hemorrhagic bullae, skin crepitus, hypotension." → Emergent surgical debridement + vancomycin + pip-tazo + clindamycin; do NOT delay for imaging.

Stem 4 — water exposure: "Cirrhotic patient ate raw oysters, rapidly progressing leg cellulitis with bullae." → Vibrio vulnificus — ceftriaxone + doxycycline, admit, surgery.

Stem 5 — bite injury: "Cat bite to hand 24 hours ago, now swelling and erythema." → Pasteurella — amoxicillin-clavulanate; tetanus update; consider hand surgery if deep.

Stem 6 — periorbital vs orbital: "Child with eyelid swelling, no proptosis, normal EOM" → preseptal — outpatient amox-clav. "With proptosis, painful EOM, vision change" → orbital — CT, admit, IV antibiotics, ENT/ophtho.

Stem 7 — failure to improve: "Cellulitis not responding after 72 hours of cephalexin." → Reassess for abscess (ultrasound), wrong organism (MRSA — add TMP-SMX or vancomycin), wrong diagnosis (stasis dermatitis, DVT).

Stem 8 — recurrent cellulitis: "Fourth episode of right leg cellulitis this year in a patient with chronic lymphedema." → Treat acute episode + prophylactic penicillin V 250 mg BID + compression + treat tinea pedis.

Stem 9 — mimicker: "Bilateral leg erythema, chronic, hyperpigmented, no fever." → Stasis dermatitis — compression, elevation, topical steroid; no antibiotics.

Stem 10 — pregnancy: "Pregnant woman with leg cellulitis." → Cephalexin (avoid doxycycline, fluoroquinolones, TMP-SMX near term).

Stem 11 — bacteremia: "S. aureus bacteremia from skin source." → Repeat blood cultures, TEE, ID consult, 14+ days IV antibiotics.

Stem 12 — PSGN: "10 days after impetigo, child has cola-colored urine, hypertension, periorbital edema, low C3." → Post-streptococcal glomerulonephritis — supportive (BP control, salt restriction); antibiotics don't prevent it.

Step 3 management: When stems offer both "admit" and "outpatient with 48h follow-up," the Eron criteria + comorbidities + ability to tolerate PO dictate the answer.

Board pearl: The wrong answer is usually "broaden antibiotics empirically" when the right answer is reassess the diagnosis or drain an occult abscess.

One-Line Recap

Cellulitis and erysipelas are clinical diagnoses managed with short-course β-lactams as outpatients when systemically well and able to tolerate PO, with admission for IV therapy reserved for systemic toxicity, comorbid decompensation, failure of outpatient therapy, or suspicion of necrotizing infection.

— Non-purulent → cover strep (cephalexin PO or cefazolin IV)

— Purulent → cover MRSA (TMP-SMX/clindamycin PO or vancomycin IV) + I&D

— Duration: 5–7 days in most uncomplicated cases

— Special exposures dictate special coverage (bites → amox-clav; salt water + cirrhotic → ceftriaxone + doxycycline)

— Class I → outpatient with 48h follow-up

— Class II–III → admit for IV antibiotics

— Class IV → ICU + emergent surgery for necrotizing infection

— Pain out of proportion, crepitus, hemorrhagic bullae, skin anesthesia, rapid progression, septic shock

— Treat tinea pedis (highest-yield modifiable risk factor)

— Compression stockings for venous insufficiency/lymphedema

— Glycemic control, weight management, foot care

— Penicillin V 250 mg BID prophylaxis if ≥3 episodes/year

Empiric therapy:

Disposition (Eron):

Red flags = surgery, not just antibiotics:

Long-term plan:

Don't miss the mimics: bilateral leg "cellulitis" = stasis dermatitis; non-responding breast erythema = inflammatory breast cancer; pain out of proportion = necrotizing fasciitis.

Board pearl: Mark the erythema border, reassess in 48 hours, treat the portal of entry, and choose the narrowest effective antibiotic — this is the entire Step 3 algorithm in one breath.